Harmony Biosciences Says New Data Supports Neurology Pipeline

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY ) shares closed higher by around 8% on Tuesday following the company's announcement of record revenue for the second quarter of 2026. The neurological disease-focused pharma company reported second quarter earnings of $1.28 per share, beating the consensus of 94 cents. Read Also: Twist Bioscience Sees AI Drug Discovery Pipeline Expand Sales reached $261.30 million, surpassing the consensus of $248.41 million. Harmony Biosciences (HRMY) Surges On Record Q2 Revenue And WAKIX Growth In its latest earnings report, Harmony Biosciences revealed that net revenue for WAKIX grew 30% year-over-year to $261.3 million, with an estimated average of 8,950 patients using the product. The company reiterated its full-year guidance for WAKIX net revenue, projecting between $1.0 billion and $1.04 billion compared to the consensus of $1.02 billion. T...